SLDB - ソリッド・バイオサイエンシズ (Solid Biosciences Inc.) ソリッド・バイオサイエンシズ

 SLDBのチャート


 SLDBの企業情報

symbol SLDB
会社名 Solid Biosciences Inc (ソリッド・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ソリッド・バイオサイエンス(Solid Biosciences Inc.)(旧名:Solid Biosciences、LLC)はライフサイエンス企業である。同社はデュシェンヌ型筋ジストロフィー(DMD)の治療法の開発に注力する。同社はDMDを対象とした遺伝子治療、疾患修正療法、補助デバイスを開発する。矯正療法プラットフォームはDMD用遺伝子治療候補の開発に従事する。リードプログラムであるSGT-001はジストロフィン遺伝子の機能性バージョンの全身送達を可能にすることに焦点を当てたアデノ随伴ウイルス(AAV)マイクロジストロフィン遺伝子治療の候補者である。同社はDMD関連二次的障害を管理するのに役立つ小分子および生物学的候補を検査する。同社はDMD患者のウェアラブルサポートを開発中である。補助装置のハードウェアは力発生アクチュエータ(またはモータ)、電気制御クラッチ、およびFlex Gripと呼ばれるハーネス技術の3つの技術で構成される。   ソリッド・バイオサイエンシズは米国のライフサイエンス企業。米国における筋ジストロフィ―の遺伝子治療の特定と開発に従事。遺伝子導入の主力候補には、患者の筋肉に機能性ジストロフィンタンパク質の発現を回復させるSGT-001があり、アデノ随伴ウイルス(AAV)ベクタ―による遺伝子治療として臨床試験を手掛ける。本社所在地はマサチュ―セッツ州ケンブリッジ。   Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, its mandate is simple yet comprehensive - work to address the disease at its core by correcting the underlying mutation that causes Duchenne with its lead gene therapy candidate, SGT-001.
本社所在地 141 Portland Street Fifth Floor Cambridge MA 02139 USA
代表者氏名 Andrey J. Zarur アンドレイ・J・ザール
代表者役職名 Chairman of the Board Co-Founder
電話番号 +1 617-337-4682
設立年月日 41334
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 60人
url www.solidbio.com
nasdaq_url https://www.nasdaq.com/symbol/sldb
adr_tso
EBITDA EBITDA(百万ドル) -62.13500
終値(lastsale) 37.35
時価総額(marketcap) 1323402381
時価総額 時価総額(百万ドル) 1212.144
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 149.385
当期純利益 当期純利益(百万ドル) -61.84900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Solid Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $11.3M to $33.9M. Higher net loss reflects Research and development increase of 41% to $23.8M (expense) General and administrative increase of 51% to $8.2M (expense) Stock-based Compensation in R&D increase from $504K to $1.7M (expense).

 SLDBのテクニカル分析


 SLDBのニュース

   Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development  2021/07/02 12:00:00 Intrado Digital Media
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior Vice President, Clinical Development, Roxana Dreghici. The grant was approved by a majority of the independent directors of the Company on June 16, 2021 as an inducement material to Dr. Dreghici entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
   Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy  2021/07/01 12:00:00 Intrado Digital Media
-Additional expertise expected to support attainment of key corporate goals-
   Life Science Firm Takes Office-Lab Space in Charlestown''s Hood Park  2021/06/24 17:04:01 CoStar
Solid Biosciences Signs New 10-Year Lease at 500 Rutherford Ave.
   Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer  2021/06/07 00:00:00 BioSpace
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Regulatory Officer, Dr. Iman Barilero.
   Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer  2021/06/07 00:00:00 BioSpace
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective Dr. Barilero brings three decades of experience as a strategic executive in the healthcare industry, successfully designing innovative and integrated regulatory pathways that gaine
   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   Solid Biosciences Announces Pricing of Public Offering of Common Stock - Stocks News Feed  2021/03/19 01:14:12 Stocks News Feed
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc., (NASDAQ:SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share, for total gross… Read More »Solid Biosciences Announces Pricing of Public Offering of Common Stock
   The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study  2021/03/16 08:17:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 15) …
   STAT+: In restarted study, Solid Bio reports no serious toxicity in Duchenne patient given ‘safer’ gene therapy  2021/03/15 20:40:24 STAT News
Solid Biosciences said it has restarted a clinical trial of its gene therapy for Duchenne muscular dystrophy without the serious safety issues that forced the study to shut down in…
   Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort  2021/03/15 20:15:00 GlobeNewswire
- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA),…
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   Solid Biosciences Inc. (NASDAQ:SLDB) CEO Ilan Ganot Sells 10,713 Shares of Stock  2021/01/30 12:14:41 Watchlist News
Solid Biosciences Inc. (NASDAQ:SLDB) CEO Ilan Ganot sold 10,713 shares of Solid Biosciences stock in a transaction dated Thursday, January 28th. The shares were sold at an average price of $6.14, for a total value of $65,777.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. SLDB […]
   Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference - Stocks News Feed  2021/01/06 12:30:00 Stocks News Feed
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 8:20… Read More »Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
   80 Biggest Movers From Yesterday  2020/12/18 09:47:14 Benzinga
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS ) shares climbed 473.7% to close at $33.96 on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma shares gained around 8% on Wednesday after the company priced its IPO at $5.5 per share. MingZhu Logistics Holdings Ltd (NASDAQ: YGMZ ) shares surged 336.4% to close at $17.50. Wunong Net Technology Company Limited (NASDAQ: WNW ) shares climbed 88.2% to close at $122.50 after jumping 440% on Wednesday. The company, on Tuesday, priced its IPO at $5 per share. Nxt-ID, Inc. (NASDAQ: NXTD ) gained 54.2% to close at $1.4250 after jumping around 90% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 47.7% to close at $5.45 after the company issued regulatory update for IV Tramadol. Boqii Holding Limited (NYSE: BQ ) rose 46.1% to close at $7.00. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) gained 34.4% to close at $9.11. Vivos Therapeutics, earlier during the month, priced its IPO at $6 a share.
   5 Top Stock Gainers for Friday: Disney, FAT Brands  2020/12/11 17:46:16 The Street
Walt Disney, vTv Therapeutics, Nanthealth, Solid Biosciences and FAT Brands are five of the top stock gainers for Friday.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ソリッド・バイオサイエンシズ SLDB Solid Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)